Drugs R D. 2010;10(4):271-84. doi: 10.2165/11588080-000000000-00000.
Tofacitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant, is being developed by Pfizer for the treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of transplant rejection. Tofacitinib specifically inhibits Janus activated kinase 3 (JAK3), which has a pivotal role in cytokine signal transduction that governs lymphocyte survival, proliferation, differentiation, and apoptosis. This review discusses the key development milestones and therapeutic trials of this drug.
托法替尼（CP-690,550；CP-690550；CP690550），一种口服免疫抑制剂，由辉瑞公司开发，用于治疗类风湿关节炎、炎症性肠病、干眼症、强直性脊柱炎、银屑病、银屑病关节炎以及预防移植排斥反应。托法替尼特异性抑制 Janus 激活激酶 3（JAK3），它在细胞因子信号转导中起着关键作用，调节淋巴细胞的存活、增殖、分化和凋亡。本文讨论了该药物的关键开发里程碑和临床试验。
